Value of Renal Vascular Doppler Sonography in Management of Decompensated Heart Failure

Not Applicable

Completed

• Conditions: Cardiorenal Syndrome
• Interventions: Drug: intravenous furosemide

• Registration Number: NCT02372292
• Lead Sponsor: Ankara University

Brief Summary

Although the traditional determinant of renal dysfunction in heart failure was suggested as decreased cardiac output and renal hypo perfusion, recent studies have demonstrated the association of persistent systemic venous congestion and kidney dysfunction. Relief of the congestion has demonstrated to improve renal functions in decompensated heart failure. The current trial was set up to investigate the changes of renal venous impedance and renal arteriolar resistivity indices with diuretic therapy, in patients with congestive renal failure. The investigators asked whether measurement of renal venous impedance index or renal arteriolar resistivity index can guide the practice of diuretic therapy.

Detailed Description

Not available

Study Timeline

• Study Start: 2013-02
• Study First Submitted: 2015-02-13
• Study First Submitted QC: 2015-02-25
• Study First Posted: 2015-02-26
• Status Verified: 2015-06
• Primary Completion: 2015-06
• Study Completion: 2015-06
• Last Update Submitted: 2015-06-22
• Last Update Posted: 2015-06-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Decompensated heart failure
• Elevated serum creatinine levels on admission

Exclusion Criteria

• Atrial fibrillation
• Obstructive uropathy
• Patients with ascites
• Patients who exposed the potential nephrotoxic drugs in the previous week (metformin, antibiotics, chemotherapeutics, iodinated contrast agents and non-steroidal anti-inflammatory agents)
• Patients who needed positive inotropic agents

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group 1	intravenous furosemide	Patients with type 1 cardiorenal syndrome who had improvement of renal functions along with diuretic therapy. Intravenous furosemide treatment.
Group 2	intravenous furosemide	Patients with type 1 cardiorenal syndrome who did not have improvement of renal functions along with diuretic therapy. Intravenous furosemide treatment.

Primary Outcome Measures

Name	Time	Method
Alterations in the renal arterial resistivity index	during hospitalization, an expected average of 4 weeks.	Participants will be followed for the duration of hospital stay, an expected average of 4 weeks.

Secondary Outcome Measures

Name	Time	Method
Alterations in the renal venous impedance index	during hospitalization, an expected average of 4 weeks.	Participants will be followed for the duration of hospital stay, an expected average of 4 weeks.

Trial Locations

Locations (1)

Ankara University School Of Medicine, Department of Cardiology; 🇹🇷 Ankara, Turkey